Loading
Gyala Therapeutics develops CAR-T cell therapy, in which a patient's own immune cells are modified to attack leukaemia. Its first product targets a protein called CD84 and is in an early trial in acute myeloid leukaemia and T-cell acute lymphoblastic leukaemia that has come back or not responded.
Gyala Therapeutics was founded in 2020 as a spin-off of Hospital Clinic Barcelona and the IDIBAPS research institute, according to the company. GYA01 is a CAR-T cell therapy targeting CD84. Spain's AEMPS authorised a phase 1/2a, open-label, single-arm trial (NCT07471789) in relapsed or refractory acute myeloid leukaemia and T-cell acute lymphoblastic leukaemia, with recruitment announced in February 2026 at Hospital La Fe in Valencia and Hospital Clinic Barcelona. In October 2024 the company announced 3 million euros from CDTI Innovation (Innvierte programme), Nara Capital and Invivo Partners, following a 1.5 million euro seed round in 2020. Its first registered cancer trial, NCT07471789, was posted on ClinicalTrials.gov in March 2026.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Venture round · 3 million euros from CDTI Innovation (Innvierte), Nara Capital and Invivo Partners; the round is not named. No US dollar figure stated. | 2024 | undisclosed | gyalatx.com |
| Seed · 1.5 million euros, as mentioned in the October 2024 release. | 2020 | undisclosed | gyalatx.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/